Table 2.
Selected characteristics of cases (N=1,136) and controls (N=922) with NAT1 and NAT2 SNP genotype data in the NCI-SEER multicenter case–control study of NHL.
| Cases | Controls | ||
|---|---|---|---|
| N(%) | N(%) | p-value* | |
| Sex | |||
| Male | 622(54.8%) | 487(52.8%) | 0.4 |
| Female | 514(45.2%) | 435(47.2%) | |
| Age (years) | |||
| < 45 | 200(17.6%) | 144(15.6%) | 0.0006 |
| 45–64 | 561(49.4%) | 398(43.2%) | |
| 65 + | 375(33.0%) | 380(41.2%) | |
| Race | |||
| White, non-Hispanic | 980(86.3%) | 743(80.6%) | < 0.0001 |
| Black | 78(6.9%) | 124(13.4%) | |
| Other | 78(6.9%) | 55(6.0%) | |
| Study center | |||
| Detroit | 232(20.4%) | 160(17.4%) | 0.1 |
| Iowa | 333(29.3%) | 257(27.9%) | |
| Los Angeles | 282(24.8%) | 238(25.8%) | |
| Seattle | 289(25.4%) | 267(29.0%) | |
| History of cigarette smoking | |||
| Nonsmoker | 208(18.3%) | 163(17.7%) | 0.1** |
| Current smoker | 80(7.0%) | 55(6.0%) | |
| Former smoker | 148(13.0%) | 147(15.9%) | |
| Missing | 700(61.6%) | 557(60.4%) | |
| Mutagenic potential | |||
| (revertant colonies/day) | |||
| Q1: 0.0–1700.0 | 79(7.0%) | 64(6.9%) | 0.2** |
| Q2: 1700.1–3416.1 | 68(6.0%) | 74(8.0%) | |
| Q3: 3416.2–6470.0 | 99(8.7%) | 68(7.4%) | |
| Q4: 6470.1–11,338.0 | 103(9.1%) | 73(7.9%) | |
| Q5: > 11,338.0 | 76(6.7%) | 69(7.5%) | |
| Missing | 711(62.6%) | 574(62.3%) | |
| DNA source | |||
| Blood | 751(66.1%) | 639(69.3%) | 0.1 |
| Buccal cells | 385(33.9%) | 283(30.7%) | |
| Case histopathology | |||
| DLBCL | 358(31.5%) | ||
| Follicular lymphoma | 269(23.7%) | ||
| SLL | 146(12.9%) | ||
| Marginal zone | 91(8.0%) | ||
| Mantle Cell | 41(3.6%) | ||
| Burkitt lymphoma | 18(1.6%) | ||
| All T-cell | 70(6.2%) | ||
| NOS | 143(12.6%) |
*
P-value for Pearson chi-square statistic.
**
P-values computed excluding those with missing data for history of cigarette smoking and diet.